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Aim To evaluate the efficacy of radiation therapy in alle-
viating pain and improving the quality of life (QoL) with 
validated questionnaires in patients with painful bone me-
tastases (BoM).
Methods This prospective, observational study recruited 
167 patients with painful BoM who were treated with pal-
liative radiotherapy (PRT) from February 2015 to February 
2018. After the first clinical assessment, the patients filled 
out specific questionnaires and underwent a fast radio-
therapy treatment within 48 hours. The patients were fol-
lowed up for eight weeks.
Results The median age was 66.30 years. The most com-
mon primary cancer was lung cancer (31.1%). The most of-
ten prescribed scheme was 8 Gy in one fraction (70%). The 
patients experienced significant pain response and im-
proved QoL compared with baseline, especially in the first 
two weeks after radiation. Overall, reduced pain and drug 
score were reported at two weeks of PRT in 68 (51.5%) and 
37 (28%) of patients, respectively.
Conclusions PRT is an effective treatment option for pa-
tients with painful BoM.
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Bone metastases (BoM) are a common health issue, as the 
bone is the third most common metastatic site of can-
cer (1). It is the most common metastatic site for breast 
cancer, and most women who died from the disease had 
BoM at death (2). About 83% of patients with BoM com-
plain of pain at some point in their life, with wide varia-
tion in the pattern and intensity of pain (3). BoM are a 
major cause of morbidity, usually leading to pain and a 
decreased quality of life (QoL) (4). Common consequenc-
es of BoM are bone fractures, which can be prevented or 
treated by radiation or surgery (5). Palliative radiotherapy 
(PRT) reduces pain in the majority of patients although it 
often takes effect only after several weeks of treatment 
(6). The conventional treatment of BoM is local-field ra-
diation therapy, leading to improvement in about 80% 
of patients (7). Patients with BoM can suffer from emer-
gency conditions, such as spinal cord compression and 
uncontrollable bleeding. In these cases, RT should start 
as soon as possible, often on the day of consultation and 
simulation, as treatment delay may cause unrecoverable 
functional loss (8). However, painful BoM is considered a 
non-emergency condition, and due to increased work-
load in the radiation unit RT may be delayed for weeks. 
This is why it is necessary to provide a rapid pathway from 
primary consultation to RT delivery. In our unit, we intro-
duced an organized rapid pathway to deliver PRT within 
48 hours after admission to the unit.
In 1991, Bruera et al (9) developed an instrument that facili-
tated and standardized the assessment of patients with pain-
ful BoM, the Edmonton Symptom Assessment Scale (ESAS), 
which evaluates nine physical and mental symptoms on a 
Likert scale. Twenty-two years later, Carvajal et al (10) validat-
ed the ESAS as a Spanish reference tool for symptom assess-
ment in advanced cancer patients. Palliative care research-
ers widely used the European Organisation for Research and 
Treatment of Cancer Quality of Life Questionnaire Core 30 
(EORTC QLQ-C30) (11,12), but it has the disadvantage of be-
ing too long. This is why an abbreviated 15-item version, the 
EORTC QLQ-C15-PAL, was created for use among patients 
with short life expectancy and advanced, symptomatic can-
cer (13). The abbreviated version was shown as a reliable and 
valid instrument for Spanish patients (14). Still, there is lim-
ited data on the efficacy of radiotherapy for palliating pain 
from BoM among patients nearing the end of life (15) ow-
ing to the lack of follow-up studies in this population. The 
systematic review by McDonald et al (16) on the use of RT 
for BoM included 26 articles, however, the included studies 
were retrospective and almost all of them lacked a pro-
spective follow-up.
The aim of this study is to present our experience in treat-
ing and following up patients with painful BoM and to 
estimate the efficacy of PRT in improving QoL with vali-
dated instruments and in alleviating pain response with 
visual analogue scale (VAS) as well as the pain and drug 
scores. Finally, we aimed to assess whether a single or 
fractional radiation dose was better at improving QoL 
and relieving pain.
PATIEnTs And METhods
study design and patients
The participants of this prospective, longitudinal, obser-
vational study were recruited among all patients with 
painful BoM who were referred for PRT in the radiothera-
py department of Virgen de las Nieves University Hospital 
(HUVN) in Granada, Spain from February 2015 to February 
2018. This hospital is one of the two public hospitals in 
the city of Granada, serving a population of over 487 000 
people. The inclusion criteria were a proven histological 
diagnosis of a solid tumor, painful BoM of any bone site 
that was not previously irradiated, and age older than 
18 years. The medical treatment of pain was performed 
in the pain care unit. Mild pain was treated with a non-
steroidal anti-inflammatory drug; acetaminophen, ibu-
profen, and indomethacin. Moderate to severe pain was 
treated with opioid therapy; with mild narcotics trama-
dol and codeine and strong narcotics fentanyl (especially 
patches), methadone, and morphine.
Patients with BoM were closely monitored for eight weeks, 
during which QoL and pain were assessed. After a clinical 
assessment, PRT was evaluated, and a scheme for RT deliv-
ery was outlined on a day-care basis. Following this, a pre-
treatment computed tomography simulation was done, 
and clinical target volume and planning target volume 
were determined according to recommendations (17). The 
patients underwent three-dimensional conformal radiation 
treatment, which is a well-recognized palliative treatment 
for painful BoM (7). The treatment schemes were from 8 Gy 
in one fraction to 30 Gy in 10 fractions. All patients previ-
ously diagnosed with BoM and referred for PRT during the 
recruitment period were eligible for participation – 169 in 
total. The primary tumor sites were the lung (31.1%), breast 
(15%), urinary bladder (10.8%), and other less frequent tu-
mor sites. Out of the 169 patients, two were not included in 
the final sample: one rejected to participate and the other 
died before treatment, leaving a final sample size of 167. All 
the patients provided an informed consent. The study was 
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approved by the Ethics Committee of the Investigation of 
the Province of Granada (PI-0439-2014).
data collection
Quality of life was evaluated with the EORTC-QLQ-C15-PAL, 
a validated questionnaire for QoL research in cancer pa-
tients that consists of 15 questions with answers on a four-
point scale. Patients had to choose the response that best 
described their state, from 1 (not at all) to 4 (very much). 
Overall QoL was rated from 1 (very poor) to 7 (excellent) 
(18). We also used the ESAS, an 11-point scale that eval-
uates nine symptoms on a scale of 0-10 (0 = absence of 
symptom and 10 = worst possible symptom). The investi-
gated symptoms were pain, fatigue, nausea, depression, 
anxiety, drowsiness, appetite, sense of well-being, and 
shortness of breath. This tool was successfully validated in 
cancer patients (19-21). Pain response was evaluated ac-
cording to Chow et al as follows: “complete pain response 
was delimited as a VAS score of 0, partial response was de-
limited as pain reduction ≥ 2 at the treated site measured 
with the VAS (0-10) and without analgesic increase, or as 
analgesic reduction ≥ 25% from baseline without worsen-
ing of pain” (22). The pain response was measured with 1) 
VAS of pain intensity that ranges from 0 to 10 (0 – no pain, 
1 to 3 – mild pain, 4 to 6 –moderate pain, and 7 to 10 – in-
tense pain), 2) the pain score (pain severity score × pain fre-
quency score) and drug score (drug severity score × drug 
frequency score) (23,24). Patients with complete or partial 
pain relief in VAS and/or the pain score were considered to 
show pain response. All the patients completed the ques-
tionnaires by themselves within 24 hours before receiv-
ing PRT (baseline). At weeks 2, 4, 6, and 8 they were con-
tacted by an experienced interviewer and completed the 
same questionnaires by telephone. This call was also used 
to check the patient’s connection with other units (pal-
liative care, medical oncology, general practitioner) and 
in some cases to continue with the next step in care. The 
rates of death, re-treatment, and hospital admissions were 
assessed.
statistical analysis
Qualitative variables at each cut-off point of the follow-
up are expressed as frequency and percentages. The 
significance of the change of the dependent variables 
during the follow-up was assessed with the Friedman’s 
non-parametric test. Survival after diagnosis was estimat-
ed with the Kaplan-Meier method. For survival analysis, 
the start date was considered the date when the individ-
ual was considered a palliative patient and the end date 
was the date of death or the end of the study (February 
2018). Statistical analyses were conducted using the SPSS 
statistical software package, version 24.0 (IBM Corp, Ar-
monk, NY, USA).
REsulTs
The median age was 66.30 years (range, 24-96). Ninety-
nine patients (59.3%) were male. A total of 149 patients un-
derwent out-patient treatment, and the average time from 
the first assessment to the first RT dose received was 2 days 
(range, 1-5). Regarding PRT, 120 (71.9%) patients received 
single fraction therapy (SFRT), while 47 (28.1%) received 
multiple fraction therapy (MFRT). The most frequently pre-
scribed scheme was 8 Gy in one fraction (70%), followed 
by 20 Gy in 5 fractions (15.6%). The most common site of 
radiation was the spine (50.9%) (Table 1).
Sixteen patients were re-irradiated to the same bone site 
due to pain relapse after an initial satisfactory response. 
Fourteen patients (8.4%) received a single-fraction dose of 
8 Gy, whereas one patient received 20 Gy in 5 fractions and 
TAblE 1. Characteristics of patients (n = 167) with painful bone 
metastases treated with palliative radiotherapy
Age no. (%)







urinary bladder 18 (10.8)
upper gastrointestinal tract 13 (7.8)
lower gastro intestinal tract 13 (7.8)
prostate 12 (7.2)




hip bone 34 (20.4)
ribs 17 (10.2)
sacrum 12 (7.2)
femur  6 (3.6)
scapula  6 (3.6)
others†  7 (4.2)
*Thyroid, parathyroid, uterus, ovary, nasopharyngeal, spine, mela-
noma, sarcoma, testicle, and unknown.
†Clavicle, humerus, and sternum.
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one 15 Gy in 5 fractions (Table 2). Twenty patients (12%) 
were admitted to the hospital due to severe, unbearable 
pain during the follow-up period. The post-radiation ther-
apy mean and median survival time was 111 days and 66 
days, respectively (95% confidence interval, 86-136 days 
and 49-82 days, respectively). A total of 37 (22.1%) of par-
ticipants died within one month of beginning radiother-
apy and 157 (94%) patients died by the end of the study 
(Figure 1). The QLQ-C15-PAL and the ESAS questionnaires 
were completed before treatment (n = 167) and at week 
2 (n = 132), week 4 (n = 103), week 6 (n = 79), and week 
8 (n = 68) after radiotherapy. The patients who finished 
the assessment had significantly improved overall QoL 
(P < 0.001). There was also a significant pain reduction as 
evaluated by VAS (mean pre-PRT VAS: 7, mean PRT VAS at 2 
and 4 weeks respectively after radiation: 5, and mean VAS 
at 6, 8 weeks respectively: 4; P < 0.001) (Table 3).
Out of 132 patients evaluated at 2 weeks after PRT, 70 
(53%) reported partial pain relief as assessed by VAS and 68 
(51.5%) as assessed by pain score (Table 4). Moreover, 14 
patients (10.6%) had partly reduced analgesic consump-
tion and 23 (17.4%) had discontinued analgesic consump-
tion at 2 weeks (Table 5). The patients who received SFRT 
did not significantly differ from the patients who received 
MFRT (Figure 2).
dIsCussIon
Our study found pain mitigation and QoL improvement 
after RT in patients with metastatic bone disease, espe-
cially during the first month after radiation. There was no 
TAblE 2. Radiation dose in patients (n = 167) with painful bone 
metastases treated with palliative radiotherapy
dose (Gy) Fraction n (%)
 8  1 117 (70)
20  5  26 (15.6)
30 10   6 (3.6)
12  3   5 (3.0)
15  5   2 (1.2)
10  2   2 (1.2)
 9  3   2 (1.2)
 8  2   2 (1.2)
 4  1   2 (1.2)
21  3   2 (1.2)
36  6   1 (0.6)
TAblE 3. Patients’ scores before and after the radiation therapy (RT)*†
before treatment At 2 weeks of RT At 4 weeks of RT At 6 weeks of RT At 8 weeks of RT p
EsAs
patients with valid data, n 167 132 103 79 68 <0.001
patients with missing data, n 0 35 64 88 99
median score (50th) 39 28 25 25 24.50
QlQ-C15-PAl
patients with valid data, n 167 132 103 79 68 <0.001
patients with missing data, n 0 35 64 88 99
median score (50th) 31 28 26 26 25
VAs
patients with valid data, n 167 132 103 79 68 <0.001
patients with missing data, n 0 35 64 88 99
median score (50th) 7 5 5 4 4
*EsAs – Edmonton symptom Assessment scale; QlQ-C15-PAl – Quality of life Questionnaire-Core 15-Palliative; VAs – visual analog scale.
†The lower the EsAs and/ or the QlQ-C15-PAl scores, the higher the quality of life. The lower the VAs score, the lower the pain.
FIGuRE 1. Kaplan-Meier post-radiation therapy survival curve 
in patients with painful bone metastases. The x-axis shows 
days until death and the y-axis shows the percent survival.
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difference between patients who received SFRT and those 
who received MFRT. This study is the study with the larg-
est number of patients with BoM (167 patients) that used 
validated QoL instruments (EORTC-QLQ-C15-PAL, ESAS), as 
well as VAS and pain and drug scores.
BoM is a common problem in patients with tumors and a 
major cause of disability. Our study presents clinical and 
evaluative research focused on patients’ outcomes. Af-
ter one month, 77% of the patients were still alive. After 
two months, however, only 52% of the patients were still 
alive and participating in the study. After three years of 
the study, most of the patients died. The main reasons for 
not completing the follow-up questionnaires were drastic 
health deterioration or death. Data were missing for a con-
siderable proportion of patients, most commonly the pa-
tients who left the follow-up in the middle of the study.
Most of studies have shown that PRT provides pain relief for 
about 60% of patients in a median of two to three weeks 
(25,26). We observed 68% of patients with pain reduction 
two weeks after irradiation. We also found that the QoL 
and pain initially improved after treatment and remained 
stable until the end of the follow-up. This stabilization is an 
TAblE 5. drug response in patients (n = 167) with painful bone metastases after receiving palliative radiation therapy (PRT)
The number (%) of patients with drug score at week after PRT
drugs consumption after PRT 2 4 6 8
Increased  12 (9.1)   8 (7.8)  6 (7.6)  4 (5.9)
stable  83 (62.9)  56 (54.4) 36 (45.6) 33 (48.5)
Partially reduced‡  14 (10.6)  14 (13.6) 17 (21.5) 13 (19.1)
discontinued  23 (17.4)  25 (24.3) 20 (25.3) 18 (26.5)
valid 132 103 79 68
missing  35  64 88 99
*drug score = drug severity score × drug frequency score. drug severity: none given = 0, analgesic = 1, mild narcotic = 2, strong narcotic = 3. drug fre-
quency: none given = 0, less than once per day = 1, once per day = 2, twice or more per day = 3. drug score was defined as discontinued = drug score 
of 0, partially reduced = decrease drug score ≥ one point, stable = same drug score before and after treatment, increased = increase drug score ≥ one 
point. drug score estimates drug consumption in relation to pre-treatment status and, therefore, pre-treatment data were not recorded.
†significant differences in drug score were found between week 2 and week 4 (P = 0.013), week 6 (P = 0.011), and week 8 (P = 0.012). non-significant 
differences were found between week 4 and week 6, between week 4 and week 8, between week 6 and week-
‡Partially reduced analgesic consumption means that strong narcotic was replaced by a mild narcotic or an analgesic, or that mild narcotic was 
replaced by analgesic, and/or that the frequency of the drug consumption was changed from twice or more per day to once or less per day.
TAblE 4. Pain evaluation in patients (n = 167) with painful bone metastases treated with palliative radiotherapy*†
Pain response
after palliative
no. (%) of patients at week
2 4 6 8
radiation therapy VAs pain score VAs pain score VAs pain score VAs pain score
Worse pain  29 (22) 23 (17.4)  19 (18.4) 12 (11.7) 16 (20.3)  7 (8.9) 14 (20.6) 10 (14.7)
no change  33 (25) 41 (31.1)  20 (19.4) 23 (22.3) 13 (16.5) 18 (22.8) 12 (17.6) 12 (17.6)
Partial pain relief  70 (53) 59 (44.7)  63 (61.2) 54 (52.4) 49 (62) 41 (51.9) 41 (60.3) 41 (60.3)
Complete pain relief  9 (6.8)   1 (1) 14 (13.6)  1 (1.3) 13 (16.5)  1 (1.5)  5 (7.4)
valid 132 103 79 68
missing  35  64 88 99
*Pain score = pain severity score × pain frequency score. Pain severity (no pain = 0, mild pain = 1, moderate pain = 2, severe pain = 3). Pain frequency 
(never pain = 0, occasional pain [less than once daily] = 1, intermittent pain [at least once daily] = 2, constant pain = 3). Pain score was defined as 
complete pain relief = pain score of 0, partial pain relief = pain score decrease ≥ one point, no change = pain score stable before and after treatment, 
worse pain = pain score increase ≥ one point. Visual analogue scale (VAs) was defined as complete pain relief = VAs score of 0. Partial pain relief = pain 
reduction ≥2 points at the treated site without analgesic increase, or as analgesic reduction ≥25% from baseline without worsening of pain. no 
change = VAs was identical when compared with the baseline. Worse pain = VAs increased. VAs and pain score estimate perceived pain in relation 
to pre-treatment status and, therefore, pre-treatment data were not recorded. Patients with complete or partial pain relief in VAs and/or pain score 
were considered as showing pain response.
†significant or borderline-significant differences in VAs score were found between week 2 and week 4 (P = 0.042), week 6 (P = 0.009), and week 8 
(P = 0.063). non-significant differences were found between week 4 and week 6, week 4 and week 8, between week 6 and week 8. significant or 
borderline-significant differences in pain score were found between week 2 and week 4 (P = 0.005), week 6 (P = 0.046), and week 8 (P = 0.086), be-
tween week 4 and week 6, week 4 and week 8. non-significant differences were found between week 6 and week 8.
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important finding, which reflects the treatment’s benefits 
since untreated patients experience decreased QoL and 
increased pain. In a retrospective study by Macchia et al 
(27) involving 160 patients with painful BoM treated with 
3D-conformal half-body irradiation (HBI), pain and drug 
scores were reduced in 76.3% and 50.4% of patients, re-
spectively. In our study, overall pain and drug scores after 
one month of PRT were 66% and 37.9%, respectively. Al-
though Macchia et al obtained a high percentage of com-
plete responses, the irradiation scheme was longer than 
the one most frequently used in our study (single dose). 
The longer scheme is not always feasible in fragile pallia-
tive cancer patients who live far from the irradiation center, 
and we believe treatment schemes should be adapted to 
patients’ clinical condition and life circumstances. Further-
more, in the study by van der Velden et al 61% patients 
achieved a complete or partial response (28), making their 
results very similar to ours.
Patients with BoM need a rapid pathway that provides 
prompt RT delivery in the most comfortable setting. In a 
previous study conducted in our department, the mean 
delay from RT unit consultation to RT initiation for BoM 
was 11 days (29). The mean delay in this study was only 
two days. This rapid treatment service satisfies the 
current patients and encourages other patients to choose 
this method of treatment.
According to Chang et al (30), a radiation oncology mod-
el integrating palliative care practice was associated with 
cost savings, shorter treatment courses, fewer hospitaliza-
tions, and increased palliative care. Moreover, Konski et al 
(31) showed that SFRT was the most cost-effective palli-
ative treatment for patients with BoM from prostate can-
cer compared with pain medication, chemotherapy, and 
MFRT. The Andalusian Health Service reported that the 
treatment cost of RT of a single location BoM with a lin-
ear accelerator, and other palliative treatments, up to a 
maximum dose of 30 Gy was € 1223.67. The cost of the 
analgesic treatment varies according to patients’ needs, ie, 
the cost of an implant of subcutaneous morphine infusion 
pump is € 139.39 (32). Furthermore, Chang et al and Tsang 
et al showed that shorter RT regimens were most cost-ef-
fective in general (30,33). Other studies also showed that 
SFRT was cost-effective and should be widely adopted for 
uncomplicated BoM (7). Our study confirms that there was 
no significant difference in the patient outcome following 
SFRT or MFRT regimens, although costs alone should not 
guide treatment decisions and should, therefore, be con-
sidered when no significant difference in treatment effi-
cacy is shown.
Palliative patients are specific patients that need all the care 
that we can offer. They need to be free from pain and dis-
tressing symptoms and to feel supported by their health 
care team. Although patients with BoM generally begin 
the treatment early enough, a rapid pathway not only ac-
celerates the treatment delivery and enhances the quality 
of medical service, but also encourages patients to opt for 
this treatment method.
The study has some limitations, mainly the small number 
of patients. However, all patients were assessed on a simi-
lar basis with validated instruments. In addition, data were 
gathered from patients with clinical records and treatment 
sheets, increasing the data reliability.
Our study also introduced the after-treatment use of vali-
dated questionnaires: EORTC-QLQ-C15-PAL, ESAS, VAS, and 
pain and drug scores. In Spain, RT as a treatment option for 
painful BoM has been applied for years, but there has been 
a lack of follow-up protocols that use validated QoL ques-
tionnaires. This study confirms the effectiveness of the pro-
tocol we have used in our center. This model not only im-
proves the QoL and reduces pain, but also makes the work 
FIGuRE 2. summarized results of quality of life (Qol) assess-
ment by the median of Edmonton symptom Assessment scale 
(EsAs). The lower the EsAs score, the higher the Qol. The 
number of patients for single-fraction radiotherapy were 167, 
94, 70, 54, 47 and 167, 38, 33, 25, 21 for multifraction radio-
therapy. Error bars represent 95% confidence intervals.
221Faris et al: Three-dimensional conformal radiation therapy in patients with painful bone metastases
www.cmj.hr
more complete, faster, smoother, and more satisfactory for 
the patients and working team. Therefore, we believe that 
our present findings can facilitate the introduction of simi-
lar models in other hospitals.
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